IP Library › Granted Patent US 12,636,375

Granted Patent B2

US 12,636,375 · App. 17/143,833 · Granted May 26, 2026

Antibodies targeting Fc receptor-like 5 and methods of use

Inventors: Renier J. Brentjens (New York, NY); Eric L. Smith (New York, NY); Cheng Liu (Emeryville, CA)

Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER; EUREKA THERAPEUTICS, INC.

C07K16/2809 A61K39/39558 A61K47/6415 A61K47/6425 A61P35/00 C07K16/2803 C07K16/283 A61K2039/572 A61K2039/585 C07K2317/21 C07K2317/31 C07K2317/34 C07K2317/622

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,636,375
App. No.: 17/143,833
Granted: May 26, 2026
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The presently disclosed subject matter provides fully human antibodies or antigen-binding fragments thereof that bind to FcRL5 and methods of using the same.

Claims (303)

1 . A nucleic acid molecule encoding an anti-Fc Receptor-Like 5 (FcRL5) antibody or an antigen-binding fragment thereof comprising a light chain variable region and a heavy chain variable region, wherein:

(aa) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:312, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:313, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:314; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:309, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:310, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:311;

(ab) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:318, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:319, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:320; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:315, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:316, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:317;

(ac) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:324, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:319, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:325; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:321, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:322, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:323;

(ad) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:329, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:330, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:331; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:326, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:327, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:328;

(ae) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:329, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:330, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:331; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:332, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:333, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:334;

(af) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:338, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:330, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:339; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:335, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:336, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:337;

(ag) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:343, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:344, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:345; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:340, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:341, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:342;

(ah) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:348, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:349, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:350; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:346, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:327, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:347;

(ai) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:352, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:344, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:353; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:346, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:327, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:351;

(aj) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:357, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:358, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:359; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:354, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:355, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:356;

(ak) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:363, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:364, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:365; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:360, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:361, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:362;

(al) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:369, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:370, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:371; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:366, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:367, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:368;

(am) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:329, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:330, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:375; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:372, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:373, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:374;

(an) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:329, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:330, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:377; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:346, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:327, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:376;

(ao) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:381, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:382, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:383; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:378, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:379, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:380;

(ap) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:329, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:385, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:386; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:309, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:310, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:384;

(aq) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:390, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:391, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:392; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:387, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:388, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:389;

(ar) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:318, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:319, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:395; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:393, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:355, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:394;

(as) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:397, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:398, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:399; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:346, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:327, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:396;

(at) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:401, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:398, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:402; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:346, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:327, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:400;

(au) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:406, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:398, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:407; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:403, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:404, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:405;

(av) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:329, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:409, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:410; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:346, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:327, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:408;

(aw) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:318, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:319, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:414; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:411, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:412, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:413;

(ax) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:416, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:417, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:418; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:411, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:412, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:415;

(ay) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:318, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:319, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:419; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:411, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:412, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:349;

(az) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:423, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:358, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:424; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:420, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:421, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:422;

(ba) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:428, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:429, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:430; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:425, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:426, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:427;

(bb) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:433, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:434, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:435; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:372, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:431, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:432;

(bc) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:423, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:438, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:439; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:436, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:388, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:437;

(bd) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:329, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:330, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:443; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:440, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:441, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:442;

(be) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:447, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:448, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:449; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:444, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:445, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:446;

(bf) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:318, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:319, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:452; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:309, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:450, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:451;

(bg) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:369, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:454, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:455; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:411, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:412, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:453;

(bh) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:318, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:319, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:457; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:411, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:412, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:456;

(bi) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:329, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:330, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:331; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:346, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:327, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:458;

(bj) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:460, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:461, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:462; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:411, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:412, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:459;

(bl) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:423, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:438, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:465; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:436, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:388, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:464;

(bm) the encoded light chain variable region comprises a CDR1 comprising the amino 479acid sequence set forth in SEQ ID NO:468, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:469, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:470; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:411, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:466, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:467;

(bn) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:474, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:358, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:465; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:471, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:472, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:473;

(bo) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:477, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:478, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:479; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:372, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:475, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:476;

(bp) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:483, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:484, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:485; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:480, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:481, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:482;

(bq) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:433, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:487, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:488; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:346, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:327, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:486;

(bs) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:312, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:313, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:493; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:309, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:310, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:492;

(bt) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:490, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:349, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:495; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:403, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:404, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:494;

(bu) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:498, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:344, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:499; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:403, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:496, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:497;

(bv) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:503, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:504, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:505; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:500, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:501, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:502;

(bw) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:508, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:349, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:509; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:403, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:506, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:507;

(bx) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:312, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:513, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:514; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:510, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:511, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:512;

(by) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:518, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:319, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:519; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:515, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:516, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:517;

(bz) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:348, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:523, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:524; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:520, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:521, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:522;

(ca) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:406, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:398, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:528; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:525, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:526, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:527;

(cb) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:318, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:319, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:530; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:411, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:412, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:529;

(cd) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:533, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:534, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:535; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:403, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:404, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:532;

(ce) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:428, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:429, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:430; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:425, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:426, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:536;

(cf) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:540, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:398, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:541; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:537, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:538, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:539;

(cg) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:406, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:398, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:542; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:537, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:538, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:539;

(ch) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:544, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:448, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:545; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:411, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:412, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:543;

(ci) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:547, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:548, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:549; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:411, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:412, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:546;

(cj) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:312, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:313, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:314; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:309, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:310, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:550;

(ck) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:312, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:513, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:314; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:309, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:310, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:550;

(cl) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:406, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:398, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:554; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:551, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:552, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:553;

(cm) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:556, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:557, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:558; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:309, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:310, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:555;

(cn) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:562, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:563, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:564; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:559, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:560, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:561;

(co) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:568, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:504, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:569; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:565, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:566, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:567;

(cq) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:343, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:575, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:576; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:403, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:404, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:574;

(cr) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:312, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:313, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:314; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:411, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:412, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:577;

(cs) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:312, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:313, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:314; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:346, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:327, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:578;

(ct) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:580, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:438, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:581; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:436, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:388, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:579;

(cu) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:585, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:313, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:314; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:582, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:583, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:584;

(cv) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:312, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:586, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:314; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:346, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:327, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:578;

(cw) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:588, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:385, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:375; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:403, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:404, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:587; or

(cx) the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:318, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:319, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:592; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:589, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:590, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:591.

2 . The nucleic acid molecule of claim 1 , wherein:

(aa) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:3, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:4;

(ab) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:7, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:8;

(ac) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:11, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:12;

(ad) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:299, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:300;

(ae) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:15, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:16;

(af) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:19, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:20;

(ag) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:23, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:24;

(ah) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:27, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:28;

(ai) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:31, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:32;

(aj) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:35, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:36;

(ak) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:39, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:40;

(al) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:43, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:44;

(am) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:47, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:48;

(an) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:51, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:52;

(ao) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:55, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:56;

(ap) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:59, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:60;

(aq) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:63, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:64;

(ar) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:67, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:68;

(as) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:71, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:72;

(at) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:75, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:76;

(au) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:79, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:80;

(av) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:83, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:84;

(aw) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:87, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:88;

(ax) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:91, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:92;

(ay) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:95, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:96;

(az) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:99, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:100;

(ba) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:103, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:104;

(bb) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:107, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:108;

(bc) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:111, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:112;

(bd) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:115, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:116;

(be) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:119, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:120;

(bf) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:123, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:124;

(bg) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:127, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:128;

(bh) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:131, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:132;

(bi) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:135, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:136;

(bj) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:139, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:140;

(bl) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:147, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:148;

(bm) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:151, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:152;

(bn) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:155, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:156;

(bo) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:159, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:160;

(bp) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:163, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:164;

(bq) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:167, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:168;

(bs) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:175, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:176;

(bt) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:179, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:180;

(bu) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:183, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:184;

(bv) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:187, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:188;

(bw) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:191, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:192;

(bx) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:195, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:196;

(by) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:199, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:200;

(bz) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:203, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:204;

(ca) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:207, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:208;

(cb) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:211, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:212;

(cd) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:219, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:220;

(ce) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:223, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:224;

(cf) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:227, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:228;

(cg) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:231, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:232;

(ch) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:235, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:236;

(ci) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:239, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:240;

(cj) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:243, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:244;

(ck) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:247, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:248;

(cl) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:251, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:252;

(cm) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:255, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:256;

(cn) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:259, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:260;

(co) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:263, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:264;

(cq) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:271, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:272;

(cr) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:275, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:276;

(cs) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:279, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:280;

(ct) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:283, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:284;

(cu) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:287, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:288;

(cv) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:291, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:292;

(cw) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:303, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:304; or

(cx) the encoded light chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:295, and the encoded heavy chain variable region comprises an amino acid sequence that has at least about 90% sequence identity to the sequence set forth in SEQ ID NO:296.

3 . The nucleic acid molecule of claim 1 , wherein:

(aa) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:3, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:4;

(ab) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:7, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:8;

(ac) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:11, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:12;

(ad) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:299, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:300;

(ae) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:15, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:16;

(af) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:19, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:20;

(ag) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:23, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:24;

(ah) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:27, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:28;

(ai) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:31, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:32;

(aj) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:35, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:36;

(ak) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:39, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:40;

(al) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:43, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:44;

(am) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:47, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:48;

(an) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:51, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:52;

(ao) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:55, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:56;

(ap) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:59, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:60;

(aq) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:63, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:64;

(ar) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:67, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:68;

(as) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:71, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:72;

(at) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:75, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:76;

(au) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:79, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:80;

(av) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:83, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:84;

(aw) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:87, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:88;

(ax) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:91, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:92;

(ay) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:95, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:96;

(az) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:99, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:100;

(ba) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:103, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:104;

(bb) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:107, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:108;

(bc) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:111, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:112;

(bd) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:115, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:116;

(be) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:119, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:120;

(bf) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:123, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:124;

(bg) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:127, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:128;

(bh) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:131, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:132;

(bi) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:135, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:136;

(bj) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:139, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:140;

(bl) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:147, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:148;

(bm) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:151, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:152;

(bn) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:155, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:156;

(bo) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:159, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:160;

(bp) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:163, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:164;

(bq) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:167, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:168;

(bs) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:175, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:176;

(bt) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:179, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:180;

(bu) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:183, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:184;

(bv) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:187, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:188;

(bw) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:191, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:192;

(bx) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:195, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:196;

(by) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:199, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:200;

(bz) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:203, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:204;

(ca) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:207, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:208;

(cb) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:211, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:212;

(cd) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:219, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:220;

(ce) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:223, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:224;

(cf) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:227, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:228;

(cg) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:231, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:232;

(ch) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:235, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:236;

(ci) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:239, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:240;

(cj) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:243, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:244;

(ck) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:247, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:248;

(cl) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:251, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:252;

(cm) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:255, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:256;

(cn) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:259, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:260;

(co) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:263, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:264;

(cq) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:271, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:272;

(cr) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:275, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:276;

(cs) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:279, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:280;

(ct) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:283, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:284;

(cu) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:287, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:288;

(cv) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:291, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:292;

(cw) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:303, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:304; or

(cx) the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:295, and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:296.

4 . The nucleic acid molecule of claim 1 , wherein the nucleic acid comprises a first nucleotide sequence encoding the light chain variable region and a second nucleotide sequence encoding the heavy chain variable region, wherein:

(aa) the first nucleotide sequence is set forth in SEQ ID NO: 1, and the second nucleotide sequence is set forth in SEQ ID NO: 2;

(ab) the first nucleotide sequence is set forth in SEQ ID NO: 5, and the second nucleotide sequence is set forth in SEQ ID NO: 6;

(ac) the first nucleotide sequence is set forth in SEQ ID NO: 9, and the second nucleotide sequence is set forth in SEQ ID NO: 10;

(ad) the first nucleotide sequence is set forth in SEQ ID NO: 13, and the second nucleotide sequence is set forth in SEQ ID NO: 14;

(ae) the first nucleotide sequence is set forth in SEQ ID NO: 17, and the second nucleotide sequence is set forth in SEQ ID NO: 18;

(af) the first nucleotide sequence is set forth in SEQ ID NO: 21, and the second nucleotide sequence is set forth in SEQ ID NO: 22;

(ag) the first nucleotide sequence is set forth in SEQ ID NO: 25, and the second nucleotide sequence is set forth in SEQ ID NO: 26;

(ah) the first nucleotide sequence is set forth in SEQ ID NO: 29, and the second nucleotide sequence is set forth in SEQ ID NO: 30;

(ai) the first nucleotide sequence is set forth in SEQ ID NO: 33, and the second nucleotide sequence is set forth in SEQ ID NO: 34;

(aj) the first nucleotide sequence is set forth in SEQ ID NO: 37, and the second nucleotide sequence is set forth in SEQ ID NO: 38;

(ak) the first nucleotide sequence is set forth in SEQ ID NO: 41, and the second nucleotide sequence is set forth in SEQ ID NO: 42;

(al) the first nucleotide sequence is set forth in SEQ ID NO: 45, and the second nucleotide sequence is set forth in SEQ ID NO: 46;

(am) the first nucleotide sequence is set forth in SEQ ID NO: 49, and the second nucleotide sequence is set forth in SEQ ID NO: 50;

(an) the first nucleotide sequence is set forth in SEQ ID NO: 53, and the second nucleotide sequence is set forth in SEQ ID NO: 54;

(ao) the first nucleotide sequence is set forth in SEQ ID NO: 57, and the second nucleotide sequence is set forth in SEQ ID NO: 58;

(ap) the first nucleotide sequence is set forth in SEQ ID NO: 61, and the second nucleotide sequence is set forth in SEQ ID NO: 62;

(aq) the first nucleotide sequence is set forth in SEQ ID NO: 65, and the second nucleotide sequence is set forth in SEQ ID NO: 66;

(ar) the first nucleotide sequence is set forth in SEQ ID NO: 69, and the second nucleotide sequence is set forth in SEQ ID NO: 70;

(as) the first nucleotide sequence is set forth in SEQ ID NO: 73, and the second nucleotide sequence is set forth in SEQ ID NO: 74;

(at) the first nucleotide sequence is set forth in SEQ ID NO: 77, and the second nucleotide sequence is set forth in SEQ ID NO: 78;

(au) the first nucleotide sequence is set forth in SEQ ID NO: 81, and the second nucleotide sequence is set forth in SEQ ID NO: 82;

(av) the first nucleotide sequence is set forth in SEQ ID NO: 85, and the second nucleotide sequence is set forth in SEQ ID NO: 86;

(aw) the first nucleotide sequence is set forth in SEQ ID NO: 89, and the second nucleotide sequence is set forth in SEQ ID NO: 90;

(ax) the first nucleotide sequence is set forth in SEQ ID NO: 93, and the second nucleotide sequence is set forth in SEQ ID NO: 94;

(ay) the first nucleotide sequence is set forth in SEQ ID NO: 97, and the second nucleotide sequence is set forth in SEQ ID NO: 98;

(az) the first nucleotide sequence is set forth in SEQ ID NO: 101, and the second nucleotide sequence is set forth in SEQ ID NO: 102;

(ba) the first nucleotide sequence is set forth in SEQ ID NO: 105, and the second nucleotide sequence is set forth in SEQ ID NO: 106;

(bb) the first nucleotide sequence is set forth in SEQ ID NO: 109, and the second nucleotide sequence is set forth in SEQ ID NO: 110;

(bc) the first nucleotide sequence is set forth in SEQ ID NO: 113, and the second nucleotide sequence is set forth in SEQ ID NO: 114;

(bd) the first nucleotide sequence is set forth in SEQ ID NO: 117, and the second nucleotide sequence is set forth in SEQ ID NO: 118;

(be) the first nucleotide sequence is set forth in SEQ ID NO: 121, and the second nucleotide sequence is set forth in SEQ ID NO: 122;

(bf) the first nucleotide sequence is set forth in SEQ ID NO: 125, and the second nucleotide sequence is set forth in SEQ ID NO: 126;

(bg) the first nucleotide sequence is set forth in SEQ ID NO: 129, and the second nucleotide sequence is set forth in SEQ ID NO: 130;

(bh) the first nucleotide sequence is set forth in SEQ ID NO: 133, and the second nucleotide sequence is set forth in SEQ ID NO: 134;

(bi) the first nucleotide sequence is set forth in SEQ ID NO: 137, and the second nucleotide sequence is set forth in SEQ ID NO: 138;

(bj) the first nucleotide sequence is set forth in SEQ ID NO: 141, and the second nucleotide sequence is set forth in SEQ ID NO: 142;

(bl) the first nucleotide sequence is set forth in SEQ ID NO: 149, and the second nucleotide sequence is set forth in SEQ ID NO: 150;

(bm) the first nucleotide sequence is set forth in SEQ ID NO: 153, and the second nucleotide sequence is set forth in SEQ ID NO: 154;

(bn) the first nucleotide sequence is set forth in SEQ ID NO: 157, and the second nucleotide sequence is set forth in SEQ ID NO: 158;

(bo) the first nucleotide sequence is set forth in SEQ ID NO: 161, and the second nucleotide sequence is set forth in SEQ ID NO: 162;

(bp) the first nucleotide sequence is set forth in SEQ ID NO: 165, and the second nucleotide sequence is set forth in SEQ ID NO: 166;

(bq) the first nucleotide sequence is set forth in SEQ ID NO: 169, and the second nucleotide sequence is set forth in SEQ ID NO: 170;

(bs) the first nucleotide sequence is set forth in SEQ ID NO: 177, and the second nucleotide sequence is set forth in SEQ ID NO: 178;

(bt) the first nucleotide sequence is set forth in SEQ ID NO: 181, and the second nucleotide sequence is set forth in SEQ ID NO: 182;

(bu) the first nucleotide sequence is set forth in SEQ ID NO: 185, and the second nucleotide sequence is set forth in SEQ ID NO: 186;

(bv) the first nucleotide sequence is set forth in SEQ ID NO: 189, and the second nucleotide sequence is set forth in SEQ ID NO: 190;

(bw) the first nucleotide sequence is set forth in SEQ ID NO: 193, and the second nucleotide sequence is set forth in SEQ ID NO: 194;

(bx) the first nucleotide sequence is set forth in SEQ ID NO: 197, and the second nucleotide sequence is set forth in SEQ ID NO: 198;

(by) the first nucleotide sequence is set forth in SEQ ID NO: 201, and the second nucleotide sequence is set forth in SEQ ID NO: 202;

(bz) the first nucleotide sequence is set forth in SEQ ID NO: 205, and the second nucleotide sequence is set forth in SEQ ID NO: 206;

(ca) the first nucleotide sequence is set forth in SEQ ID NO: 209, and the second nucleotide sequence is set forth in SEQ ID NO: 210;

(cb) the first nucleotide sequence is set forth in SEQ ID NO: 213, and the second nucleotide sequence is set forth in SEQ ID NO: 214;

(cd) the first nucleotide sequence is set forth in SEQ ID NO: 221, and the second nucleotide sequence is set forth in SEQ ID NO: 222;

(ce) the first nucleotide sequence is set forth in SEQ ID NO: 225, and the second nucleotide sequence is set forth in SEQ ID NO: 226;

(cf) the first nucleotide sequence is set forth in SEQ ID NO: 229, and the second nucleotide sequence is set forth in SEQ ID NO: 230;

(cg) the first nucleotide sequence is set forth in SEQ ID NO: 233, and the second nucleotide sequence is set forth in SEQ ID NO: 234;

(ch) the first nucleotide sequence is set forth in SEQ ID NO: 237, and the second nucleotide sequence is set forth in SEQ ID NO: 238;

(ci) the first nucleotide sequence is set forth in SEQ ID NO: 241, and the second nucleotide sequence is set forth in SEQ ID NO: 242;

(cj) the first nucleotide sequence is set forth in SEQ ID NO: 245, and the second nucleotide sequence is set forth in SEQ ID NO: 246;

(ck) the first nucleotide sequence is set forth in SEQ ID NO: 249, and the second nucleotide sequence is set forth in SEQ ID NO: 250;

(cl) the first nucleotide sequence is set forth in SEQ ID NO: 253, and the second nucleotide sequence is set forth in SEQ ID NO: 254;

(cm) the first nucleotide sequence is set forth in SEQ ID NO: 257, and the second nucleotide sequence is set forth in SEQ ID NO: 258;

(cn) the first nucleotide sequence is set forth in SEQ ID NO: 261, and the second nucleotide sequence is set forth in SEQ ID NO: 262;

(co) the first nucleotide sequence is set forth in SEQ ID NO: 265, and the second nucleotide sequence is set forth in SEQ ID NO: 266;

(cq) the first nucleotide sequence is set forth in SEQ ID NO: 273, and the second nucleotide sequence is set forth in SEQ ID NO: 274;

(cr) the first nucleotide sequence is set forth in SEQ ID NO: 277, and the second nucleotide sequence is set forth in SEQ ID NO: 278;

(cs) the first nucleotide sequence is set forth in SEQ ID NO: 281, and the second nucleotide sequence is set forth in SEQ ID NO: 282;

(ct) the first nucleotide sequence is set forth in SEQ ID NO: 285, and the second nucleotide sequence is set forth in SEQ ID NO: 286;

(cu) the first nucleotide sequence is set forth in SEQ ID NO: 289, and the second nucleotide sequence is set forth in SEQ ID NO: 290;

(cv) the first nucleotide sequence is set forth in SEQ ID NO: 293, and the second nucleotide sequence is set forth in SEQ ID NO: 294;

(cw) the first nucleotide sequence is set forth in SEQ ID NO: 297, and the second nucleotide sequence is set forth in SEQ ID NO: 298; or

(cx) the first nucleotide sequence is set forth in SEQ ID NO: 301, and the second nucleotide sequence is set forth in SEQ ID NO: 302.

5 . The nucleic acid molecule of claim 1 , wherein the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:533, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:534, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:535; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:403, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:404, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:532.

6 . The nucleic acid molecule of claim 1 , wherein the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:544, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:448, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:545; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:411, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:412, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:543.

7 . The nucleic acid molecule of claim 1 , wherein the encoded light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:329, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:330, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:443; and the encoded heavy chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:440, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:441, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:442.

8 . The nucleic acid molecule of claim 1 , wherein the encoded antigen-binding fragment is a single chain variable fragment (scFv).

9 . The nucleic acid molecule of claim 8 , wherein the encoded antibody or antigen-binding fragment thereof further comprises a peptide linker; and comprises the amino acid sequence set forth in SEQ ID NO:594, SEQ ID NO:596, SEQ ID NO:598, SEQ ID NO:600, SEQ ID NO:602, SEQ ID NO:604, SEQ ID NO:606, SEQ ID NO:608, SEQ ID NO:610, SEQ ID NO:612, SEQ ID NO:614, SEQ ID NO:616, SEQ ID NO:618, SEQ ID NO:620, SEQ ID NO:622, SEQ ID NO:624, SEQ ID NO:626, SEQ ID NO:628, SEQ ID NO:630, SEQ ID NO:632, SEQ ID NO:634, SEQ ID NO:636, SEQ ID NO:638, SEQ ID NO:640, SEQ ID NO:642, SEQ ID NO:644, SEQ ID NO:646, SEQ ID NO:648, SEQ ID NO:650, SEQ ID NO:652, SEQ ID NO:654, SEQ ID NO:656, SEQ ID NO:658, SEQ ID NO:660, SEQ ID NO:662, SEQ ID NO:666, SEQ ID NO:668, SEQ ID NO:670, SEQ ID NO:672, SEQ ID NO:674, SEQ ID NO:676, SEQ ID NO:680, SEQ ID NO:682, SEQ ID NO:684, SEQ ID NO:686, SEQ ID NO:688, SEQ ID NO:690, SEQ ID NO:692, SEQ ID NO:694, SEQ ID NO:696, SEQ ID NO:698, SEQ ID NO:702, SEQ ID NO:704, SEQ ID NO:706, SEQ ID NO:708, SEQ ID NO:710, SEQ ID NO:712, SEQ ID NO:714, SEQ ID NO:716, SEQ ID NO:718, SEQ ID NO:720, SEQ ID NO:722, SEQ ID NO:724, SEQ ID NO:728, SEQ ID NO:730, SEQ ID NO:732, SEQ ID NO:734, SEQ ID NO:736, SEQ ID NO:738, SEQ ID NO:740, SEQ ID NO:742, or SEQ ID NO:744.

10 . The nucleic acid molecule of claim 9 , wherein the nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:593, SEQ ID NO:595, SEQ ID NO:597, SEQ ID NO:599, SEQ ID NO:601, SEQ ID NO:603, SEQ ID NO:605, SEQ ID NO:607, SEQ ID NO:609, SEQ ID NO:611, SEQ ID NO:613, SEQ ID NO:615, SEQ ID NO:617, SEQ ID NO:619, SEQ ID NO:621, SEQ ID NO:623, SEQ ID NO:625, SEQ ID NO:627, SEQ ID NO:629, SEQ ID NO:631, SEQ ID NO:633, SEQ ID NO:635, SEQ ID NO:637, SEQ ID NO:639, SEQ ID NO:641, SEQ ID NO:643, SEQ ID NO:645, SEQ ID NO:647, SEQ ID NO:649, SEQ ID NO:651, SEQ ID NO:653, SEQ ID NO:655, SEQ ID NO:657, SEQ ID NO:659, SEQ ID NO:661, SEQ ID NO:665, SEQ ID NO:667, SEQ ID NO:669, SEQ ID NO:671, SEQ ID NO:673, SEQ ID NO:675, SEQ ID NO:679, SEQ ID NO:681, SEQ ID NO:683, SEQ ID NO:685, SEQ ID NO:687, SEQ ID NO:689, SEQ ID NO:691, SEQ ID NO:693, SEQ ID NO:695, SEQ ID NO:697, SEQ ID NO:701, SEQ ID NO:703, SEQ ID NO:705, SEQ ID NO:707, SEQ ID NO:709, SEQ ID NO:711, SEQ ID NO:713, SEQ ID NO:715, SEQ ID NO:717, SEQ ID NO:719, SEQ ID NO:721, SEQ ID NO:723, SEQ ID NO:727, SEQ ID NO:729, SEQ ID NO:731, SEQ ID NO:733, SEQ ID NO:735, SEQ ID NO:737, SEQ ID NO:739, SEQ ID NO:741, or SEQ ID NO:743.

11 . The nucleic acid molecule of claim 3 , wherein the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:219; and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:220.

12 . The nucleic acid molecule of claim 3 , wherein the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:235; and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:236.

13 . The nucleic acid molecule of claim 3 , wherein the encoded light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:115; and the encoded heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:116.

14 . An expression vector comprising the nucleic acid molecule of claim 1 .

15 . A host cell comprising the expression vector of claim 14 .

Assignments (3)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2021

From: LIU, CHENG

To: EUREKA THERAPEUTICS, INC.

Reel/Frame 056285/0849 →

CONFIRMATORY PATENT ASSIGNMENT Recorded Apr 14, 2021

From: SMITH, ERIC L.

To: MEMORIAL SLOAN-KETTERING CANCER CENTER

Reel/Frame 055928/0159 →

CONFIRMATORY PATENT ASSIGNMENT Recorded Mar 11, 2021

From: BRENTJENS, RENIER J.

To: MEMORIAL SLOAN-KETTERING CANCER CENTER

Reel/Frame 055569/0987 →

Continuity (4)

Division 15997155 · Jun 4, 2018

Continuation PCTUS2016064550 · Dec 2, 2016

Provisional Application 62263586 · Dec 4, 2015

Related Publication 20210388081A1 · Dec 16, 2021

References Cited (201)

US 4956778A · Naito · 1990 [cited by applicant]

US 5091513A · Huston et al. · 1992 [cited by applicant]

US 5132405A · Huston et al. · 1992 [cited by applicant]

US 5399346A · Anderson et al. · 1995 [cited by applicant]

US 5840344A · Fukushima · 1998 [cited by applicant]

US 7129053B1 · Reiter et al. · 2006 [cited by applicant]

US 7446190B2 · Sadelain et al. · 2008 [cited by applicant]

US 7521541B2 · Eigenbrot et al. · 2009 [cited by applicant]

US 8344111B2 · Bachmann et al. · 2013 [cited by applicant]

US 8389282B2 · Sadelain et al. · 2013 [cited by applicant]

US 8399645B2 · Campana et al. · 2013 [cited by applicant]

US 8497118B2 · Jensen · 2013 [cited by applicant]

US 8802374B2 · Jensen · 2014 [cited by applicant]

US 10913796B2 · Brentjens et al. · 2021 [cited by applicant]

US 11059891B2 · Brentjens et al. · 2021 [cited by applicant]

US 20050196754A1 · Drmanac et al. · 2005 [cited by applicant]

US 20100228007A1 · Hoogenboom et al. · 2010 [cited by applicant]

US 20100260748A1 · Elkins et al. · 2010 [cited by applicant]

US 20110171125A1 · Elkins et al. · 2011 [cited by applicant]

US 20140243504A1 · Davis et al. · 2014 [cited by applicant]

US 20150098900A1 · Ebens et al. · 2015 [cited by applicant]

US 20170275362A1 · Brentjens et al. · 2017 [cited by applicant]

US 20180371085A1 · Brentjens et al. · 2018 [cited by applicant]

RU 2412947C2 · 2011 [cited by applicant]

WO WO1995006748A1 · 1995 [cited by applicant]

WO WO2002002641A2 · 2002 [cited by applicant]

WO WO2006034488A2 · 2006 [cited by applicant]

WO WO2006039238A2 · 2006 [cited by applicant]

WO WO2006076691A2 · 2006 [cited by applicant]

WO WO2010114940A1 · 2010 [cited by applicant]

WO WO2010120561A1 · 2010 [cited by applicant]

WO WO2014087010A1 · 2014 [cited by applicant]

WO WO2014134165A1 · 2014 [cited by applicant]

WO WO2014191128A1 · 2014 [cited by applicant]

WO WO2014210064A1 · 2014 [cited by applicant]

WO WO2015142675A2 · 2015 [cited by applicant]

WO WO2016090337A1 · 2016 [cited by applicant]

WO WO2017096120A1 · 2017 [cited by applicant]

U.S. Appl. No. 17/332,853, filed May 27, 2021, Brentjens et al. [cited by applicant]

Polson et al., “FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma,” Blood 114(22):3836 2 pgs. (2009). [cited by applicant]

Wang et al., “Overview of Research on Immunoglobuin Fc Receptors in Newborn Animals,” Chinese Journal of Animal Husbandry 42(5):42-44 (2006) [with English abstract]. [cited by applicant]

U.S. Appl. No. 15/997,155 (U.S. Pat. No. 10,913,796), filed Jun. 4, 2018 (Feb. 9, 2021). [cited by applicant]

U.S. Appl. No. 15/614,108 (US 2017/0275362), filed Jun. 5, 2017 (Sep. 28, 2017). [cited by applicant]

U.S. Appl. No. 15/997,155, filed Dec. 9, 2020 Issue Fee Payment. [cited by applicant]

U.S. Appl. No. 15/997,155, filed Sep. 10, 2020 Notice of Allowance. [cited by applicant]

U.S. Appl. No. 15/997,155, filed Jun. 26, 2020 Response to Restriction Requirement. [cited by applicant]

U.S. Appl. No. 15/997,155, filed Mar. 27, 2020 Restriction Requirement. [cited by applicant]

Allen, “Ligand-Targeted Therapeutics in Anticancer Therapy,” Nat. Rev. Cancer 2:750-763 (2002). [cited by applicant]

Altschul et al., “Basic Local Alignment Search Tool,” J. Mol. Biol. 215:403-410 (1990). [cited by applicant]

Altschul et al., “Gapped Blast and PSI-Blast: a new generation of protein database search programs,” Nucleic Acids Res. 25(17):3389-3402 (1997). [cited by applicant]

An et al., “Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value,” Haematologic… [cited by applicant]

Anderson, “Prospects for Human Gene Therapy,” Science 226(4673):401-409 (1984). [cited by applicant]

Arnon et al., “Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy,” in Monoclonal Antibodies and Cancer Therapy, Reisfeld et al. (eds.), pp. 243-256 Alan R. Liss, Inc. (1985). [cited by applicant]

Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons Inc., New York, 2003. [cited by applicant]

Azinovic et al., “Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies,” Cancer Immunol. Immunother. 55:1451-1458 (2006). [cited by applicant]

U.S. Appl. No. 15/614,108, filed Apr. 2, 2020 Restriction Requirement. [cited by applicant]

U.S. Appl. No. 15/614,108, filed Aug. 3, 2020 Response to Restriction Requirement. [cited by applicant]

U.S. Appl. No. 15/614,108, filed Oct. 7, 2020 Non-Final Office Action. [cited by applicant]

U.S. Appl. No. 15/614,108, filed Feb. 5, 2021 Response to Non-Final Office Action. [cited by applicant]

U.S. Appl. No. 15/614,108, filed Feb. 23, 2021 Notice of Allowance. [cited by applicant]

Bataille et al., “The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy,” Haematologica 91:1234-1240 (2006). [cited by applicant]

Benton et al., “Screening λgt Recombinant Clones by Hybridization to Single Plaques in situ,” Science 196(4286):180-182 (1977). [cited by applicant]

Bertilaccio et al., “Low-Dose Lenalidomide Improves CAR-Based Immunotherapy in CLL by Reverting T-Cell Defects In Vivo,” Blood 122:4171 (2013). [cited by applicant]

Bird et al., “Single-Chain Antigen-Binding Proteins,” Science 242(4877):423-426 (1988). [cited by applicant]

Blömer et al., “Highly Efficient and Sustained Gene Transfer in Adult Neurons with a Lentivirus Vector,” Journal of Virology 71(9):6641-6649 (1997). [cited by applicant]

Boissel et al., “Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity,” Oncoimmunology, 2(10):e26527 (2013). [cited by applicant]

Boyd et al., “The Clinical Impact and Molecular Biology of del(17p) in Multiple Myeloma Treated with Conventional or Thalidomide-Based Therapy,” Genes, Chromosomes & Cancer 50:765-774 (2011). [cited by applicant]

Bregni et al., “Human Peripheral Blood Hematopoietic Progenitors are Optimal Targets of Retroviral-Mediated Gene Transfer,” Blood 80(6):1418-1422 (1992). [cited by applicant]

Brennan et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal,” Science 229(4708):81-83 (1985). [cited by applicant]

Brentjens et al., “CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia,” Science Translational Medicine 5:177ra38 (2013). [cited by applicant]

Brentjens et al., “Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15,” Nature Medicine 9(3):279-286 (2003). [cited by applicant]

Brentjens et al., “Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts,” Clin Cancer Res 13(18):5426-5435 (2007). [cited by applicant]

Brentjens et al., “Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias,” Blood 118(18):4817-4828 (2011). [cited by applicant]

Brigham et al., “Rapid Communication: In vivo Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle,” Am. J. Med. Sci. 298(4):278-281 (1989). [cited by applicant]

Brocks et al., “A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono- and bivalent scFv derivative in insect cells,” Immunotechnology 3:173-184 (1997). [cited by applicant]

Brown et al., “Tolerance to single, but not multiple, amino acid replacements in antibody V-H CDR2: A means of mm1mlzmg B cell wastage from somatic hypermutation?” The J Immunol, 156(9):3285-3291 (1996). [cited by applicant]

Caron et al., “Engineered Humanized Dimeric Forms of IgG are More Effective Antibodies,” J. Exp. Med 176:1191-1195 (1992). [cited by applicant]

Cayouette et al., “Adenovirus-Mediated Gene Transfer of Ciliary Neurotrophic Factor can Prevent Photoreceptor Degeneration in the Retinal Degeneration (rd) Mouse,” Human Gene Therapy 8:423-430 (1997). [cited by applicant]

Colman, “Effects of amino acid sequence changes on antibody-antigen interactions,” Research in Immunology, 145(1):33-36 (1994). [cited by applicant]

Cornetta et al., “Gene Transfer into Primates and Prospects for Gene Therapy in Humans,” Progress in Nucleic Acid Research and Molecular Biology 36:311-322 (1987). [cited by applicant]

Cuesta et al., Multivalent antibodies: when design surpasses evolution, Trends in Biotechnology 28(7):355-362 (2010). [cited by applicant]

Danos et al., “Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges,” Proc. Natl. Acad Sci. USA 85:6460-6464 (1988). [cited by applicant]

Davila et al., “Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia,” Science Translational Medicine 6:224ra25 (2014). [cited by applicant]

Dement-Brown et al., “Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes,” Journal of Leukocyte Biology 91:59-67 (2012). [cited by applicant]

Dudley et al., “Adoptive Cell Therapy for Patients with Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens,” J Clin Oncol 26(32):5233-5239 (2008). [cited by applicant]

Dupont et al., “Artificial Antigen-Presenting Cells Transduced with Telomerase Efficiently Expand Epitope-Specific, Human Leukocyte Antigen-Restricted Cytotoxic T Cells,” Cancer Res 65(12):5417-5427 (2005). [cited by applicant]

Eglitis et al., “Retroviral Vectors for Introduction of Genes into Mammalian Cells,” BioTechniques 6(7):608-614 (1988). [cited by applicant]

Elkins et al., “FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma,” Molecular Cancer Therapeutics 11(10):2222-2232 (2012). [cited by applicant]

Felgner et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,” Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). [cited by applicant]

Fife et al., “Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist,” J Clin Invest 116(8):2252-2261 (2006). [cited by applicant]

Flatman et al., “Process analytics for purification of monoclonal antibodies,” J. Chromatogr. B 848:79-87 (2007). [cited by applicant]

Franco et al., “Human Fc Receptor-Like 5 Binds Intact IgG via Mechanisms Distinct from Those of Fc Receptors,” Journal of Immunology 190:5739-5746 (2013). [cited by applicant]

Friedman, “Progress toward Human Gene Therapy,” Science 244(4910):1275-1281 (1989). [cited by applicant]

Frigyesi et al., “Robust isolation of malignant plasma cells in multiple myeloma,” Blood 123(9):1336-1340 (2014). [cited by applicant]

Gade et al., “Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes,” Cancer Res 65(19):9080-9088 (2005). [cited by applicant]

Gahrton et al., “Allogeneic Bone Marrow Transplantation in Multiple Myeloma,” Bone Marrow Transplantation in Multiple Myeloma, The New England Journal of Medicine 325(18):1267-1273 (1991). [cited by applicant]

Garfall et al., “Immunotherapy with Chimeric Antigen Receptors for Multiple Myeloma,” Discov Med., 17(91):37-46 (2014). [cited by applicant]

Gershoni et al., “Epitope mapping—The first step in developing epitope-based vaccines,” Biodrugs, 21 (3): 145-156 (2007). [cited by applicant]

Giomarelli et al., “Inhibition of thrombin-inducedplatelet aggregation using human single-chain Fv antibodies specific for TREM-like transcript-I,” Thromb Haemost 97:955-963 (2007). [cited by applicant]

Glennie et al., “Preparation and performance of bispecific F(ab′ gamma)2 antibody containing thioether-linked Fab′ gamma fragments,” J. Immunol. 139:2367-2375 (1987). [cited by applicant]

Gong et al., “Cancer Patient T Cells Genetically Targeted to Prostate-Specific Membrane Antigen Specifically Lyse Prostate Cancer Cells and Release Cytokines in Response to Prostate-Specific Membrane Antigen,” Neoplasia… [cited by applicant]

Grunstein et al., “Colony hybridization: A method for the isolation of clofted DNAs that contain a specific gene,” Proc. Nat. Acad. Sci., USA 72(10):3961-3965 (1975). [cited by applicant]

Guide to Molecular Cloning Techniques, Guide to Molecular Cloning Techniques, vol. 152, eds. Berger and Kimmel 1987, Academic Press, New York. [cited by applicant]

Harris et al., “Crystallographic Structure of an Intact IgG1 Monoclonal Antibody,” Journal of Molecular Biology 275:861-872 (1998). [cited by applicant]

Hatzivassiliou et al., “IRTA1 and IRTA2, Novel Immunoglobulin Superfamily Receptors Expressed in B Cells and Involved in Chromosome 1q21 Abnormalities in B Cell Malignancy,” Immunity 14:277-289 (2001). [cited by applicant]

Hellstrom et al., “Antibodies for Drug Delivery,” in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-653 (Marcel Dekker, Inc. 1987). [cited by applicant]

Ho et al., “Inhibition of Cocaine Binding to the Human Dopamine Transporter by a Single Chain Anti-Idiotypic Antibody: its Cloning, Expression and Functional Properties,” BioChim Biophys Acta 1638(3):257-266 (2003). [cited by applicant]

Hollyman et al., “Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy,” J Immunother 32:169-180 (2009). [cited by applicant]

Hughes et al., “Retroviral Gene Transfer to Primitive Normal and Leukemic Hematopoietic Cells Using Clinically Applicable Procedures,” J. Clin. Invest. 89:1817-1824 (1992). [cited by applicant]

Hunder et al., “Treatment of Metastatic Melanoma with Autologous CD4+ T cells against NY-ESO-1,” N Engl J Med 358:2698-2703 (2008). [cited by applicant]

Huston et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]

International Search Report dated Mar. 11, 2016 in International Application No. PCT/US15/64134. [cited by applicant]

International Search Report mailed May 8, 2017 in International Application No. PCT/US16/64550. [cited by applicant]

Ise et al. “Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera,” Clinical Chemistry and Laboratory Medicine 44(5):594-602 (2006). [cited by applicant]

Ise et al., “Elevation of Soluble CD307 (IRTA2/FcRH5) Protein in the Blood and Expression on Malignant Cells of Patients with Multiple Myeloma, Chronic Lymphocytic Leukemia, and Mantle Cell Lymphoma,” Leukemia 21:169-17… [cited by applicant]

Ise et al., “Immunoglobulin Superfamily Receptor Translocation Associated 2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal Antibodies,” Clinical Cancer Research 11:87-96 (2005). [cited by applicant]

Johnson, “Gene Therapy for Cystic Fibrosis,” Chest 107:77S-83S (1995). [cited by applicant]

Kabat et al. Sequences of Proteins of Immunological Interest, vol. I, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 (1991). [cited by applicant]

Kabat et al., Sequences of Proteins of Immunological Interest, 4th Edition, U. S. Department of Health and Human Services, National Institutes of Health (1987). [cited by applicant]

Karpovsky et al., “Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fcγ Receptor Antibodies,” J. Exp. Med. 160:1686-1701 (1984). [cited by applicant]

Kershaw et al., “Gene-Engineered T Cells as a Superior Adjuvant Therapy for Metastatic Cancer,” J Immunol 173:2143-2150 (2004). [cited by applicant]

Kido et al., “Use of a retroviral vector with an internal opsin promoter to direct gene expression to retinal photoreceptor cells,” Current Eye Research 15:833-844 (1996). [cited by applicant]

Kimmel, “Identification and Characterization of Specific Clones: Strategy for Confirming the Validity of Presumptive Clones,” Methods in Enzymology 152:507-511 (1987). [cited by applicant]

Klechevsky et al., “Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts,” Cancer Res. 68(15):6360-6367 (2008). [cited by applicant]

Kochenderfer et al., “Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells,” Blood, 116(19):3875-3886 (2010). [cited by applicant]

Koyko et al., “Immunology,” translated from English, edited by N.B. Serebryanaya, Mosow, “Akademiya,” 2008, p. 37 (in Russian). [cited by applicant]

Krause et al., “Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes,” J. Exp. Med. 188(4):619-626 (1998). [cited by applicant]

Le Gal La Salle et al., “An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain,” Science 259(5097):988-990 (1993). [cited by applicant]

Ledbetter et al., “Agonistic Activity of a CD40-Specific Single-Chain Fv Constructed from the Variable Regions of mAb G28-5,” Crit Rev Immunol 17:427-435 (1997). [cited by applicant]

Liu et al., “Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes,” PNAS USA 82:8648-8652 (1985). [cited by applicant]

Long et al., “4-1BB Costimulation Ameliorates T cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors,” Nat Med 21(6):581-590 (2015). [cited by applicant]

Lyddane et al., “Cutting Edge: CD28 Controls Dominant Regulatory T cell Activity during Active Immunization,” J Immunol. 176:3306-3310 (2006). [cited by applicant]

Maher et al., “Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor,” Nat. Biotechnol. 20:70-75 (2002). [cited by applicant]

Mariuzza et al., “The Structural Basis of Antigen-Antibody Recognition,” Annual Review of Biophysis and Biophysical Chemistry, 16:139-159 (1987). [cited by applicant]

Mccafferty et al., “Phage antibodies: filamentous phage displaying antibody variable domains,” Nature, 348:552-554 (1990). [cited by applicant]

Meyers et al., “Optimal alignments in linear space,” Cabios 4(1): 11-17 (1988). [cited by applicant]

Miller et al., “Cloning and Expression of a Yeast Ubiquitin-Protein Cleaving Activity in [cited by applicant]

Miller et al., “Generation of Helper-Free Amphotropic Retroviruses That Transduce a Dominant-Acting, Methotrexate-Resistant Dihydrofolate Reductase Gene,” Mol Cell Biol. 5(3):431-437 (1985). [cited by applicant]

Miller et al., “Redesign of Retrovirus Packaging Cell Lines to Avoid Recombination Leading to Helper Virus Production,” Mol. Cell. Biol. 6(8):2895-2902 (1986). [cited by applicant]

Miller, “Retrovirus Packaging Cells,” Human Gene Therapy 1:5-14 (1990). [cited by applicant]

Miyoshi et al., “Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector,” Proc. Natl. Acad. Sci. USA 94:10319-10323 (1997). [cited by applicant]

Moen, “Directions in Gene Therapy,” Blood Cells 17:407-416 (1991). [cited by applicant]

Moosmayer et al., “A single-chain TNF receptor antagonist is an effective inhibitor of TNF mediated cytotoxicity,” Therapeutic Immunol 2:31-40 (1995). [cited by applicant]

Morgan et al., “Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes,” Science 314:126-129 (2006). [cited by applicant]

Morgan et al., “Case Report of a Serious Adverse Event Following the Administration of T cells Transduced with a Chimeric Antigen Receptor Recognizing ERBB2,” Molecular Therapy 18(4):843-851 (2010). [cited by applicant]

Naldini et al., “In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector,” Science 272(5259):263-267 (1996). [cited by applicant]

Needleman et al., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,” J. Mol. Biol. 48:443-453 (1970). [cited by applicant]

Ono et al., “Plasmid DNAs directly injected into mouse brain with lipofectin can be incorporated and expressed by brain cells,” Neuroscience Letters 117:259-263 (1990). [cited by applicant]

Ozhegov et al. “Dictionary of a Russian Language: 80,000 words and phraseological expressions,” 4th ed. Supplemented, Mosow, “OOO ‘A Temp’” 2006, p. 375. [cited by applicant]

Panelli et al., “A Tumor-Infiltrating Lymphocyte from a Melanoma Metastasis with Decreased Expression of Melanoma Differentiation Antigens Recognizes MAGE-12,” J Immunol 164:4382-4392 (2000). [cited by applicant]

Panelli et al., “Expansion of Tumor-T Cell Pairs from Fine Needle Aspirates of Melanoma Metastases,” J Immunol 164:495-504 (2000). [cited by applicant]

Papanicolaou et al., “Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele,” Blood 102:2498-2505 (2003). [cited by applicant]

Parkman R., “Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones,” J. Immunol. 136(10):3543-3548 (1986). [cited by applicant]

Pastan et al., “Overview Immunotoxins in cancer therapy,” Curr. Opin. Investig. Drugs 3(7):1089-1091 (2002). [cited by applicant]

Paulus, “Preparation and Biomedical Applications of Bispecific Antibodies,” Behring Inst. Mitt. 78:118-132 (1985). [cited by applicant]

Payne, “Progress in immunoconjugate cancer therapeutics,” Cancer Cell 3:207-212 (2003). [cited by applicant]

Pegram et al., “Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning,” Blood 119(18):4133-4141 (2012). [cited by applicant]

Perez De La Lastra et al., “Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP),” Immunology, 96:663-670 (1999). [cited by applicant]

Persic et al., “An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries,” Gene 187:9-18 (1997). [cited by applicant]

Peter et al., “Protective effects of an anti-melanocortin-4 receptor scFv derivative in lipopolysaccharide-induced cachexia in rats,” J Cachexia Sarcopenia Muscle 4:79-88 (2013). [cited by applicant]

Peter et al., “scFv Single Chain Antibody Variable Fragment as Inverse Agonist of the Æ2-Adrenergic Receptor,” J Biol. Chem 278(38):36740-36747 (2003). [cited by applicant]

Riviere et al., “Novel Strategies for Cancer Therapy: The Potential of Genetically Modified T Lymphocytes,” Curr Hematol Rep 3:290-297 (2004). [cited by applicant]

Roberts et al., “Vaccination with CD20 peptides induces a biologically active, specific immune response in mice,” Blood 99:3748-3755 (2002). [cited by applicant]

Roitt et al., Immunology, Moscow, “Mir”, pp. 110-111 (2000) (in Russian with an English translation). [cited by applicant]

Rosenberg et al., “Adoptive cell transfer: a clinical path to effective cancer immunotherapy,” Nat. Rev. Cancer 8:299-308 (2008). [cited by applicant]

Rosenberg et al., “Gene Transfer Into Humans—Immunotherapy of Patients With Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction,” N Engl J Med 323:570-578 (1990). [cited by applicant]

Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Immunology, Proc. Natl. Acad. Sci. USA, 79:1979-1983 (1982). [cited by applicant]

Sadelain et al., “Targeting Tumours With Genetically Enhanced T Lymphocytes,” Nat Rev Cancer 3:35-45 (2003). [cited by applicant]

Sadelain et al., “The basic principles of chimeric antigen receptor (CAR) design,” Cancer Discovery 3(4):388-398 (2013). [cited by applicant]

Sadelain et al., “The promise and potential pitfalls of chimeric antigen receptors,” Curr Opin Immunol 21:215-223 (2009). [cited by applicant]

Sakahara et al. “Effect of DTPA Conjugation on the Antigen Binding Activity and Biodistribution of Monoclonal Antibodies Against α-Fetoprotein,” J Nucl Med, 26:750-755 (1985). [cited by applicant]

Sambrook, Fritsch and Maniatis, Molecular Cloning: A Laboratory Manual (2d ed.), CSH Press, 1989. [cited by applicant]

Sharp, “Gene Therapy,” The Lancet 337:1277-1278 (1991). [cited by applicant]

Shaughnessy Jr., et al., “A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1,” Blood 109(6):2276-2284 (2007). [cited by applicant]

Shen et al., “Engineering Peptide Linkers for scFv Immunosensors,” Anal Chem. 80(6):1910-1917 (2008). [cited by applicant]

Shieh et al., “Transgenic Expression of Single-Chain Anti-CTLA-4 Fv on β Cells Protects Nonobese Diabetic Mice from Autoimmune Diabetes,” J Immunol. 183:2277-2285 (2009). [cited by applicant]

Siegel et al., “Cancer Statistics, 2013,” CA Cancer J Clin 63:11-30 (2013). [cited by applicant]

Singer et al., Genes and Genomes, Moscow, “Mir”, pp. 63-64 (1998) (in Russian with an English translation). [cited by applicant]

Stephan et al., “T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection,” Nat. Med 13(12):1440-1449 (2007). [cited by applicant]

Straubinger et al., “Liposomes as Carriers for Intracellular Delivery of Nucleic Acids,” Methods in Enzymology 101:512-527 (1983). [cited by applicant]

Supplementary European Search Report dated Apr. 30, 2018 in Application No. EP 15864773. [cited by applicant]

Supplementary Partial European Search Report dated Sep. 30, 2019 in EP Application No. 16871553. [cited by applicant]

Tai et al., “Antibody-Based Therapies in Multiple Myeloma,” Bone Marrow Research Article ID: 924058 14 pg. (2011). [cited by applicant]

Tang et al., “The Foxp3+ regulatory T cell: a jack of all trades, master of regulation,” Nat Immunol 9(3):239-244 (2008). [cited by applicant]

Thorpe et al., “The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates,” Immunol. Rev., 62:119-158 (1982). [cited by applicant]

Thorpe, “Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review,” in Monoclonal Antibodies '84: Biological and Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985). [cited by applicant]

Tolstoshev et al., “Gene expression using retroviral vectors,” Current Opinion in Biotechnology 1:55-61 (1990). [cited by applicant]

Tomimatsu et al., “Production of Human Monoclonal Antibodies against FcεRIα by a Method Combining in Vitro Immunization with Phage Display,” Biosci Biotechnol Biochem 73(7):1465-1469 (2009). [cited by applicant]

Trail et al., “Monoclonal antibody drug immunoconjugates for targeted treatment of cancer,” Cancer Immunol. Immunother. 52:328-337 (2003). [cited by applicant]

Wahl et al., “Investigative Nuclear Medicine,” J. Nucl Med. 24:316-325 (1983). [cited by applicant]

Wahl et al., “Molecular Hybridization of Immobilized Nucleic Acids: Theoretical Concepts and Practical Considerations,” Methods Enzymol. 152:399-407 (1987). [cited by applicant]

Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]

Wolff et al., “Direct Gene Transfer into Mouse Muscle in Vivo,” Science 247(4949):1465-1468 (1990). [cited by applicant]

Wu et al., “Receptor-mediated Gene Delivery and Expression in Vivo,” Journal of Biological Chemistry 263(29):14621-14624 (1988). [cited by applicant]

Wu et al., “Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements in Vivo,” Journal of Biological Chemistry 264(29):16985-16987 (1989). [cited by applicant]

Xie et al., “Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist ScFv,” Nat Biotech 15:768-771 (1997). [cited by applicant]

Xu et al., “Correction of the enzyme deficiency in hematopoietic cells of Gaucher patients using a clinically acceptable retroviral supernatant transduction protocol,” Exp. Hemat. 22:223-230 (1994). [cited by applicant]

Yasmina et al., “Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors,” Protein Science 17:1326-1335 (2008). [cited by applicant]

Yeger, L., “Clinical Immunology and Allergology” vol. 1, 219-222 Book (1990). [cited by applicant]

Zhao et al., “Characteristics of an scFv Antibody Fragment That Binds to Immunoglobulin G of Graves' Disease Patients and Inhibits Autoantibody-Mediated Thyroid-Stimulating Activity,” Hybridoma 27(6):445-451 (2008). [cited by applicant]

Zhong et al., “Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication,” Mol Ther 18(2):413-420 (2010). [cited by applicant]